Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 1:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,638 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Control Comparator Clear all
Completed Phase 1Phase 2 Interventional Results available

Dexmedetomidine for the Control of Post-Operative Pain in Thoracotomy Patients

NCT00345384
View directory record Official record
Conditions
Post-operative Pain, Respiratory Depression
Interventions
Dexmedetomidine, Placebo (Normal Saline)
Drug · Other
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years to 85 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 7, 2016 · Synced Sep 4, 2026, 1:35 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

First Safety Study in Humans of a Single Dose of CPG 52364

NCT00547014
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Placebo Comparator: Cohort 1 Placebo, 52364 3 mg, Placebo Comparator: Cohorts 2, 3, 4 & 5 Two subjects each arm will be assigned to receive placebo, 52364 10 mg, 52364 30 mg, 52364 100 mg, 52364 1 mg
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 18, 2009 · Synced Sep 4, 2026, 1:35 AM EDT
Not yet recruiting Not applicable Interventional

Smoking Cessation Intervention for Young Adults Using MTM: A Randomized Controlled Trial

NCT07104006
View directory record Official record
Conditions
Tobacco Use Disorder/Cigarette Smoking
Interventions
Multi-Theory Model (MTM)-Based Smoking Cessation Program
Behavioral
Lead sponsor
University of Nevada, Las Vegas
Other
Eligibility
18 Years to 29 Years
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Aug 10, 2025 · Synced Sep 4, 2026, 1:35 AM EDT
Completed Not applicable Interventional Results available

Encouraging Judicious Prescribing of Opioids in Los Angeles County

NCT03856593
View directory record Official record
Conditions
Substance-Related Disorders
Interventions
Standard letter, Comparator letter
Behavioral
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
541 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 27, 2023 · Synced Sep 4, 2026, 1:35 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, and Pharmacokinetics of Single Doses of APN1125 in Healthy Normal Subjects

NCT02331433
View directory record Official record
Conditions
Schizophrenia
Interventions
APN1125, Placebo
Drug
Lead sponsor
CoMentis
Industry
Eligibility
18 Years to 65 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Apr 7, 2016 · Synced Sep 4, 2026, 1:35 AM EDT
Completed Phase 3 Interventional

Study Of Treximet, Formerly Known as Trexima, In The Acute Treatment Of Multiple Migraine Attacks

NCT00240617
View directory record Official record
Conditions
Migraine Disorders
Interventions
sumatriptan succinate/naproxen sodium, placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
623 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
52
States / cities
Anniston, Alabama • Tuscaloosa, Alabama • Mesa, Arizona + 48 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2016 · Synced Sep 4, 2026, 1:35 AM EDT
Active, not recruiting Phase 2 Interventional

A Study to Evaluate VXA-CoV2-3.3 COVID-19 Vaccine Against Currently Approved/Authorized mRNA COVID-19 Injectable Booster Vaccine in Adults Previously Immunized Against COVID-19 Infection

NCT06672055
View directory record Official record
Conditions
SARS-CoV2, COVID-19
Interventions
VXA-CoV2-3.1, COMIRNATY®, VXA-CoV2-3.3
Biological
Lead sponsor
Vaxart
Industry
Eligibility
18 Years and older
Enrollment
5,485 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
145
States / cities
Anniston, Alabama • Birmingham, Alabama • Mobile, Alabama + 126 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Sep 4, 2026, 1:35 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Single-Session Intervention Targeting Self-Injurious Behavior in Adolescents

NCT04498143
View directory record Official record
Conditions
Nonsuicidal Self Injury, Self Hatred, Suicidal Thoughts, Suicide Attempts
Interventions
Project SAVE ("Stop Adolescent Violence Everywhere") SSI, Active Comparator: Supportive Therapy ("Share Your Feelings") SSI
Other
Lead sponsor
University of Denver
Other
Eligibility
13 Years to 16 Years
Enrollment
565 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 9, 2024 · Synced Sep 4, 2026, 1:35 AM EDT
Not yet recruiting Not applicable Interventional

Quadratus Lumborum Versus Placebo in Open Ventral Hernia Repair

NCT06953635
View directory record Official record
Conditions
Hernia, Ventral, Pain Management
Interventions
Quadratus Lumborum (QL) Block, Placebo
Procedure
Lead sponsor
University of Tennessee Graduate School of Medicine
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 30, 2025 · Synced Sep 4, 2026, 1:35 AM EDT
Completed Phase 4 Interventional Results available

Efficacy, Safety, and Pharmacokinetics of Sugammadex for Reversal of Neuromuscular Blockade (NMB) in Pediatric Participants (MK-8616-089)

NCT03351608
View directory record Official record
Conditions
Neuromuscular Blockade
Interventions
Sugammadex 2 mg/kg, Sugammadex 4 mg/kg, Neostigmine + Glycopyrrolate, Neostigmine + Atropine
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
2 Years to 16 Years
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
11
States / cities
Los Angeles, California • Palo Alto, California • San Diego, California + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2021 · Synced Sep 4, 2026, 1:35 AM EDT
Completed Not applicable Interventional

Implementation Science Approach to Enhancing Depression Treatment in Collaborative Depression Care Settings ( DepCare )

NCT05085886
View directory record Official record
Conditions
Depressive Symptoms
Interventions
DepCare, Enhanced Usual Care
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
605 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 13, 2025 · Synced Sep 4, 2026, 1:35 AM EDT
Completed Phase 2 Interventional Results available

Study of the Effect of Intradialytic Vasopressin on Chronic Hypertension in Patients With End Stage Renal Disease

NCT01247090
View directory record Official record
Conditions
Hypertension, End Stage Renal Disease
Interventions
Vasopressin - Very Low Dose, Vasopressin - Low Dose, Placebo Comparator
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 17, 2019 · Synced Sep 4, 2026, 1:35 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Clinical Study to Evaluate the Safety, Immunogenicity and Efficacy of Investigational Flu Vaccine Compared to Approved Flu Vaccine in Children.

NCT01964989
View directory record Official record
Conditions
Influenza Virus
Interventions
Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV), Non-adjuvanted Trivalent Influenza Vaccine (TIV) / Quadrivalent Influenza Vaccine (QIV)
Biological
Lead sponsor
Seqirus
Industry
Eligibility
6 Months to 71 Months
Enrollment
10,644 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
91
States / cities
Chandler, Arizona • Harrisburg, Arkansas • Anaheim, California + 70 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2023 · Synced Sep 4, 2026, 1:35 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly in Subjects With Type 2 Diabetes Mellitus (DURATION-5)

NCT00877890
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
exenatide once weekly, exenatide twice daily
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
41
States / cities
Birmingham, Alabama • Mesa, Arizona • Peoria, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2015 · Synced Sep 4, 2026, 1:35 AM EDT
Active, not recruiting Phase 2 Interventional

4D-150 in Patients With Diabetic Macular Edema

NCT05930561
View directory record Official record
Conditions
Diabetic Macular Edema, Diabetic Retinopathy
Interventions
4D-150 IVT, Aflibercept IVT
Biological
Lead sponsor
4D Molecular Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
5
States / cities
Hagerstown, Maryland • Eugene, Oregon • Erie, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 4, 2026, 1:35 AM EDT
Completed Phase 3 Interventional Results available

Placebo Controlled Trial of Valproate and Risperidone in Young Children With Bipolar Disorders

NCT00221403
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Risperidone oral solution, Valproate Oral Solution, Placebo
Drug · Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
3 Years to 7 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
2
States / cities
Cincinnati, Ohio • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Sep 4, 2026, 1:35 AM EDT
Completed Phase 3 Interventional Results available

Evaluate Efficacy and Safety of Fingolimod 0.5 mg Orally Once Daily Versus Placebo in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients.

NCT01625182
View directory record Official record
Conditions
Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Interventions
Fingolimod, Placebo Comparator
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
12
States / cities
Orange, California • Miami, Florida • St. Petersburg, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2017 · Synced Sep 4, 2026, 1:35 AM EDT
Recruiting Phase 3 Interventional

Study of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell Disease

NCT07247188
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
PCV21, 20vPCV
Biological
Lead sponsor
Sanofi
Industry
Eligibility
2 Years to 17 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
5
States / cities
Atlanta, Georgia • Omaha, Nebraska • New Brunswick, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Sep 4, 2026, 1:35 AM EDT
Completed Phase 2 Interventional

VK2735 for Weight Management Phase 2

NCT06068946
View directory record Official record
Conditions
Weight Loss
Interventions
VK2735, Placebo
Biological
Lead sponsor
Viking Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
20
States / cities
Birmingham, Alabama • Long Beach, California • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2025 · Synced Sep 4, 2026, 1:35 AM EDT
Completed Phase 3 Interventional Results available

Effects of Pioglitazone on High-density Lipoprotein (HDL) Function in Persons With Diabetes

NCT01156597
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
pioglitazone
Drug
Lead sponsor
University of Miami
Other
Eligibility
35 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 20, 2014 · Synced Sep 4, 2026, 1:35 AM EDT
Completed Phase 2 Interventional

A Phase 2 Study to Evaluate the Safety and Efficacy of CB-03-01 Solution, a Comparator Solution and Vehicle Solution in Males With Androgenetic Alopecia

NCT02279823
View directory record Official record
Conditions
Androgenetic Alopecia
Interventions
CB-03-01 solution, Minoxidil Solution 5%, Placebo solution
Drug
Lead sponsor
Intrepid Therapeutics, Inc.
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
3
States / cities
San Diego, California • Fridley, Minnesota • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 12, 2017 · Synced Sep 4, 2026, 1:35 AM EDT
Completed Not applicable Interventional Results available

Clinical Investigation (Beta) of Power Knee Mainstream - Dynamic

NCT04787627
View directory record Official record
Conditions
Prosthesis User, Amputation
Interventions
Power Knee
Device
Lead sponsor
Össur Iceland ehf
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
2
States / cities
Silver Spring, Maryland • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 21, 2025 · Synced Sep 4, 2026, 1:35 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

SWITCH Diets Study: Self-monitoring With Internet Technology to Choose Healthy Diets

NCT06245369
View directory record Official record
Conditions
Overweight and Obesity, Pre-diabetes
Interventions
learning modules (within app), SWITCH app (self-regulation features) - Experimental, SWITCH app (self-regulation features) - Comparator
Behavioral
Lead sponsor
University of South Carolina
Other
Eligibility
18 Years to 65 Years
Enrollment
106 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Mar 20, 2025 · Synced Sep 4, 2026, 1:35 AM EDT
Completed Phase 3 Interventional

SLV 308 and Pramipexole for Treatment of Patients With Early Parkinson Disease

NCT00335166
View directory record Official record
Conditions
Early Stage Parkinson Disease
Interventions
Pardaprunox, pramipexole, Placebo Comparator
Drug
Lead sponsor
Solvay Pharmaceuticals
Industry
Eligibility
30 Years and older
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
17
States / cities
Birmingham, Alabama • Oceanside, California • Oxnard, California + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2008 · Synced Sep 4, 2026, 1:35 AM EDT